Table 2.
Summary of hormone receptor and HER-2 expression in salivary gland tumors
| BENIGN | |||||||
|---|---|---|---|---|---|---|---|
| Tumor type | Number of cases |
ER (n = 120) |
PR (n = 120) |
AR (n = 118)a |
HER-2 (n = 119)b |
||
| Pleomorphic adenoma | 91 | 28 (31%) 17 W, 11 M |
5 (5%) 3 W, 2 M |
12 (13%) 10 W, 2 M |
0 | ||
| Warthin tumor | 23 | 10 (43%) 7 W, 3 M |
0 | 1 (4%) W | 0 | ||
| Basal cell adenoma | 2 | 2 (100%) M | 0 | 0 | 0 | ||
| Monomorphic adenoma | 2 | 0 | 0 | 0 | 0 | ||
| Oncocytoma | 2 | 0 | 0 | 0 | 0 | ||
| Total | 120 | 40 (33%) 24 W, 16 M |
5 (4%) 3 W, 2 M |
13 (11%) 11 W, 2 M |
0 | ||
| MALIGNANT | |||||
|---|---|---|---|---|---|
| Tumor type | Number of cases |
ER (n = 134) |
PR (n = 134) |
AR (n = 132)a |
HER-2 (n = 133)b |
| Salivary duct carcinoma | 25 (All high grade) |
3 (12%) W | 1 (4%) W | 25 (100%) 2 W, 3 M, 20 S |
19 (76%) |
| Adenoid cystic carcinoma | 26 (Eight high grade/dedifferentiated) |
5 (19%) 3 W, 2 M |
3 (12%) 1 W, 2 M |
3 (12%) 2 W, 1 M |
1 (4%) (High grade) |
| Acinic cell carcinoma | 16 (Ten high grade/dedifferentiated) |
1 (6%) W | 0 | 3 (19%) 1 W, 1 M, 1 S (1 S = high grade) |
4 (25%) (All high grade) |
| Mucoepidermoid carcinoma | 16 (Five intermediate and six high grade) |
2 (13%) W | 1 (6%) W | 0 | 2 (13%) (Both high grade) |
| Poorly differentiated carcinoma, not otherwise specified | 16 (All high grade) |
2 (13%) M | 0 | 6 (38%) 1 W, 2 M, 3 S |
5 (31%) |
| Carcinoma ex pleomorphic adenoma | 10 (Eight invasive and high grade) |
3 (30%) 2 W, 1 M |
2 (20%) 1 W, 1 M |
7 (70%) 2 W, 3 M, 2 S (2 S = high grade) |
2 (20%) (Both high grade) |
| Polymorphous adenocarcinoma | 6 (One cribriform variant) |
4 (67%) 1 W, 3 M |
2 (33%) 1 W, 1 M |
2 (33%) 1 W, 1 M |
0 |
| Squamous cell carcinoma | 8 (All high grade) |
2 (25%) 1 W, 1 M |
0 | 1 (13%) S | 3 (38%) |
| Mammary analogue secretory carcinoma | 5 (Two high grade) |
2 (40%) 1 W, 1 M |
0 | 2 (40%) M | 0 |
| Oncocytic carcinoma | 4 (One intermediate and two high grade) |
2 (50%) 1 W, 1 M |
0 | 2 (50%) S (One intermediate and one high grade) | 3 (75%) (One intermediate and two high grade) |
| Intraductal carcinoma | 1 | 0 | 0 | 1 S (100%) | 1 (100%) |
| Myoepithelial carcinoma | 1 | 0 | 0 | 0 | 0 |
| Total | 134 | 26 (19%) 15 W, 11 M |
9 (7%) 5 W, 4 M |
52 (39%) 9 W, 13 M, 30 S |
40 (30%) |
| Total High Grade or Dedifferentiated | 85 | 15 (18%) 9 W, 6 M |
3 (4%) 2 W, 1 M |
42 (49%) 5 W, 9 M, 28 S |
38 (45%) |
ER estrogen receptor, PR progesterone receptor, AR androgen receptor, W weak, M moderate, S strong
aOne pleomorphic adenoma, one monomorphic adenoma, and two adenoid cystic carcinomas were missing from the AR TMA slides
bOne pleomorphic adenoma and one adenoid cystic carcinoma was missing from the HER-2 TMA slides